Recent Updates
Recently added Catalysts
ENGN Positive Sentiment

enGene to Participate in Upcoming Investor Conferences

Friday, November 6, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: enGene Therapeutics announced its participation in two upcoming investor conferences. The UBS Global Biopharma Conference is scheduled for November 16, 2026, while the Jefferies Global Healthcare Conference will take place on November 19, 2026. These events will feature management discussions aimed at engaging with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • enGene is actively engaging with investors.
  • Participation in notable conferences enhances visibility.
  • Management's involvement suggests confidence in the company's direction.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+19%
120-day peak, hindsight
Typical move
4.1%
average across 2 past catalysts
Cash runway
~40 mo
Low dilution risk
Lead asset
EG-70
Phase 2 · Superficial Bladder Cancer

Full Press Release Details

BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company today announced that management will participate in the following investor conferences: UBS Global Biopharma Conference 2026 Date: Monday, November 16, 2026 Time: 3:20 p.m. GMT / 10:20 a.m. ET Format: Fireside Chat Jefferies Global Healthcare Conference in London Date: Thursday, November 19, 2026 Time: 10:30 a.m. GMT / 5:30 a.m. ET Format:

Frequently Asked Questions

What conferences will enGene participate in?

enGene will participate in the UBS and Jefferies conferences in November 2026.

When is the UBS Global Biopharma Conference?

The UBS Global Biopharma Conference is on November 16, 2026.

What time is enGene's presentation at UBS?

enGene's presentation at UBS is scheduled for 3:20 p.m. GMT.

Where will the Jefferies Global Healthcare Conference be held?

The Jefferies Global Healthcare Conference will be held in London.

ShareAdd on Google
Tags: ENGN enGene investor conferences UBS Global Biopharma Jefferies Global Healthcare Nasdaq: ENGN
Last updated: Nov 6, 2026

Biotech snapshot

Cash runway
$266M liquidity · $6M/mo burn
~40 mo
Low dilution risk
Lead asset
EG-70Phase 2
Superficial Bladder Cancer →

Catalyst track record

+19%
best trade around ENGN's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for ENGN.

See every catalyst's timing & PoA →